← Back to Search

Kinase Inhibitor

Acalabrutinib + Venetoclax + Rituximab for Mantle Cell Lymphoma (TrAVeRse Trial)

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 67 months
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a combination of three drugs to treat patients with a specific type of lymphoma who haven't been treated before. The goal is to see if this combination can effectively eliminate cancer cells and if patients can stop treatment without the cancer coming back. The treatment works by blocking growth signals, killing cancer cells, and boosting the immune system. Rituximab, combined with chemotherapy, has been shown to be highly effective in treating indolent lymphomas.

Who is the study for?
This trial is for adults with newly diagnosed Mantle Cell Lymphoma (MCL) who need treatment and have not received any prior therapies for MCL. They should be in clinical Stage II, III, or IV, able to consent, and have at least one measurable site of disease. Participants must agree to use effective contraception and cannot join if they are pregnant or breastfeeding, have severe illnesses that could affect the study's safety or outcomes, active infections like HIV/Hepatitis B/C, other active cancers (with some exceptions), significant heart issues, or known allergies to the drugs being tested.
What is being tested?
The TrAVeRse study tests a combination of Acalabrutinib plus Venetoclax and Rituximab (AVR) in treatment-naïve MCL patients. It aims to see how many achieve MRD-negative complete remission after 13 cycles of AVR. Those who do will either continue with Acalabrutinib or enter observation. If participants progress during observation, they may receive Acalabrutinib again.
What are the potential side effects?
Possible side effects include diarrhea; headache; fever; fatigue; muscle pain; bruising; nausea; constipation; vomiting; rash as well as more serious ones such as bleeding problems, high blood pressure, irregular heartbeat among others.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 67 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 67 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MRD-negative CR rate
Secondary study objectives
Complete Response (CR) rate
Duration of Response (DoR)
Event Free Survival (EFS)
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Acalabrutinib + Venetoclax + RituximabExperimental Treatment3 Interventions
Acalabrutinib + Venetoclax + Rituximab (AVR)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
1999
Completed Phase 4
~2990
Venetoclax
2019
Completed Phase 3
~2240
Acalabrutinib
2020
Completed Phase 2
~2080

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Mantle Cell Lymphoma (MCL) treatments often target specific pathways crucial for cancer cell survival and proliferation. Acalabrutinib, a Bruton's Tyrosine Kinase (BTK) inhibitor, blocks BTK, a protein essential for B-cell receptor signaling, thereby inhibiting the growth and survival of malignant B-cells. Venetoclax targets B-cell lymphoma 2 (BCL-2) proteins, promoting cancer cell apoptosis. Rituximab is a monoclonal antibody that binds to the CD20 antigen on B-cells, marking them for destruction by the immune system. These targeted therapies are significant for MCL patients as they offer more precise and effective treatment options with potentially fewer side effects compared to traditional chemotherapy.

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,411 Previous Clinical Trials
289,122,964 Total Patients Enrolled

Media Library

Acalabrutinib (Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05951959 — Phase 2
Mantle Cell Lymphoma Research Study Groups: Acalabrutinib + Venetoclax + Rituximab
Mantle Cell Lymphoma Clinical Trial 2023: Acalabrutinib Highlights & Side Effects. Trial Name: NCT05951959 — Phase 2
Acalabrutinib (Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05951959 — Phase 2
~72 spots leftby Jul 2028